Archive for 2007/09


Teen Asthma: The Role Of Leisure Activities

A German study on some 3,000 teenagers shows that the risk of developing wheezing is greater among those who regularly go to discotheques than among sports or computing enthusiasts. Smoking is still, however, the main behavioural factor contributing to asthma, concludes the study, to be published in the European Respiratory Journal (ERJ), the official publication of the European Respiratory Society (ERS). [click link for full article]
(more...)


Choline, An Alternative Therapy For Asthma

The prevalence of asthma has increased worldwide and current therapies for the disease, such as glucocorticoids, are limited in their usefulness, due to potential side effects. Bhanu Pratap Singh (Allergy and Immunology Section, Institute of Genomics and Integrative Biology, Delhi, India) and his team examined the anti-inflammatory effects of choline via oral or intranasal routes in mice model of allergic asthma. [click link for full article]
(more...)


Offering Choice To Tuberculosis Patients Improves Treatment Outcomes

Tuberculosis (TB) is an important disease. More than a third of the world's population has been infected with the disease. Given the right conditions, these infections can progress from latent to active disease. Even in Europe, TB is increasing in several countries. If latent TB infection is treated effectively, then many individuals can be prevented from developing TB and passing it on to their friends and families before they realise they are ill. [click link for full article]
(more...)


Government Launches Winter Flu Campaign, UK

"Flu could seriously affect the health of over two million younger people in 'at risk' groups such as those with asthma or diabetes", the Chief Medical Officer said as he urged them to get their flu jab this winter. A new campaign starting on Monday marks the start of flu season and encourages those in 'at risk' groups or over 65 years of age to get the jab. [click link for full article]
(more...)


Dey L.P. And Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets For The Chronic Treatment Of Asthma

Dey, L.P., an affiliate of Merck KGaA of Darmstadt, Germany, announced that it has launched ZYFLO CR(TM) (zileuton) extended release tablets with its marketing partner, Critical Therapeutics, Inc. (Nasdaq: CRTX). ZYFLO CR(TM) offers twice-daily, extended-release dosing for the prevention and chronic treatment of asthma in patients 12 years of age and older. [click link for full article]
(more...)


Oral Drug Candidate for theTtreatment of Pneumocystis Pneumonia - Chinese SFDA Grants Immtech Fast Track Status

Immtech Pharmaceuticals, Inc. (Immtech) (Amex: IMM) announced that the State Food and Drug Administration of the People's Republic of China (SFDA) has granted Immtech's application Fast Track Status for conducting a Phase III clinical trial with pafuramidine, the Company's oral drug candidate for the treatment of Pneumocystis pneumonia (PCP). [click link for full article]
(more...)


Sharp Intake Of Breath As 99% Of Smokers Respect The Ban, UK

After just three months of smokefree public places in England, research published by ASH (Action on Smoking & Health), Asthma UK and the British Thoracic Society shows 97% of smokers are respecting the ban fully or quitting smoking completely, leaving the rest of us to breathe a sigh of relief. Three quarters (73%) of adults say the new law has been good for their health. [click link for full article]
(more...)


New Cutting Edge Pain Relief Treatments - Electrical Currents And Acupuncture Release The Body’s Natural Pain Relievers

Empowering chronic pain sufferers and their practitioners, The Journey to Pain Relief describes an innovative pain management approach that taps into the body's inherent ability to heal. [click link for full article]
(more...)


Radical Research Results On The Oxidation Of Vitamin E

Recent research results have challenged conventional understanding of the oxidation of the "radical scavenger", vitamin E. Cutting-edge analysis methods have revealed that the intermediates commonly believed to be involved in the process do not occur. This surprising finding has been systematically documented and published as part of a project supported by the Austrian Science Fund FWF. [click link for full article]
(more...)


Pediatric Asthma Programs Featuring PARI Pharma’s EFlow - Pediatric Asthma Development Programs, USA

The rights to Verus Pharmaceuticals' pediatric asthma development programs that utilize PARI's eFlow electronic nebulizer for aerosol delivery were acquired by AstraZeneca. Following Gilead Sciences' acquisition of Corus Pharma in August 2006, this is the second major pharmaceutical acquisition where a licensed eFlow is featured prominently in the development pipeline. [click link for full article]
(more...)